Cargando...

The Breakthrough of Biosimilars: A Twist in the Narrative of Biological Therapy

The coming wave of patent expiries of first generation commercialized biotherapeutical drugs has seen the global market open its doors to close copies of these products. These near perfect substitutes, which are termed as “biosimilars”, do not need to undergo intense clinical trials for their approv...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Biomolecules
Main Authors: Kabir, Eva Rahman, Moreino, Shannon Sherwin, Sharif Siam, Mohammad Kawsar
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2019
Assuntos:
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6770099/
https://ncbi.nlm.nih.gov/pubmed/31450637
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/biom9090410
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!